59.55
Incyte Corp stock is traded at $59.55, with a volume of 1.87M.
It is down -0.10% in the last 24 hours and down -1.23% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$59.61
Open:
$59.95
24h Volume:
1.87M
Relative Volume:
0.94
Market Cap:
$12.13B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
425.36
EPS:
0.14
Net Cash Flow:
$16.80M
1W Performance:
-4.96%
1M Performance:
-1.23%
6M Performance:
-27.68%
1Y Performance:
+9.53%
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
INCY
Incyte Corp
|
59.55 | 12.13B | 4.08B | 32.48M | 16.80M | 0.14 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.82 | 130.98B | 11.10B | -988.90M | -978.00M | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 64.65B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
622.93 | 39.39B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
276.55 | 34.32B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
232.25 | 28.03B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Dec-17-24 | Initiated | UBS | Neutral |
Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
Oct-01-24 | Initiated | Wolfe Research | Outperform |
Sep-18-24 | Downgrade | Truist | Buy → Hold |
Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
May-23-24 | Initiated | Deutsche Bank | Hold |
Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
Feb-23-24 | Initiated | Jefferies | Buy |
Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
Jul-25-23 | Initiated | Citigroup | Buy |
May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
Jan-31-23 | Initiated | Piper Sandler | Overweight |
Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jan-07-21 | Initiated | Truist | Buy |
Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
Jun-16-20 | Initiated | The Benchmark Company | Hold |
May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-24-20 | Resumed | William Blair | Outperform |
Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Feb-04-20 | Resumed | BofA/Merrill | Neutral |
Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
Oct-03-19 | Initiated | Mizuho | Buy |
Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
May-21-19 | Initiated | Credit Suisse | Neutral |
May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
Apr-11-19 | Initiated | Stifel | Hold |
Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360
US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments - GlobeNewswire Inc.
Incyte Reports Strong Q1 2025 Financial Results and Pipeline Progress - MyChesCo
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Incyte to Present at Upcoming Investor Conference - Business Wire
Incyte (INCY) Target Price Raised Following Strong Q1 Performanc - GuruFocus
9 Analysts Have This To Say About IncyteIncyte (NASDAQ:INCY) - Benzinga
Incyte (INCY) Target Price Raised Following Strong Q1 Performance | INCY Stock News - GuruFocus
Incyte (INCY) Receives Adjusted Price Target from TD Cowen | INC - GuruFocus
BofA Boosts Incyte (INCY) Price Target Following Q1 Results | IN - GuruFocus
Incyte (INCY) Target Price Raised by Wells Fargo Despite Mixed R - GuruFocus
Steroid Refactory Acute Graft-Versus-Host Disease Market Growth Projections 2023-2032: DelveInsight Analysis | MaaT Pharma, Medac GmbH, AltruBio Inc., Incyte Corporation - Barchart.com
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript - Insider Monkey
Incyte: Q1 Earnings Snapshot - CT Insider
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Reve - GuruFocus
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MSN
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises - Investing.com
BofA raises Incyte stock price target to $89, maintains Buy rating - Investing.com
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises By Investing.com - Investing.com Canada
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - BioSpace
Incyte Corp Raises Jakafi Sales Forecast Following Strong Performance - Finimize
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key P - GuruFocus
Incyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Incyte Q1 2025 slides: 26% product revenue growth, Jakafi guidance raised - Investing.com
Incyte Corp (INCY) Q1 2025 Earnings: EPS of $0.80 Beats Estimate, Revenue Surges to $1.053 Billion - GuruFocus
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs | INCY Stock News - GuruFocus
Incyte Q1 Results Top Estimates - Nasdaq
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key Products | INCY Stock News - GuruFocus
Incyte earnings beat by $0.12, revenue topped estimates - Investing.com
Incyte Reports 2025 First Quarter Financial Results - TradingView
Incyte (INCY) Set to Announce Q1 Earnings, Analysts Cautious - GuruFocus
Incyte (INCY) Q1 Earnings Report Preview: What To Look For - Barchart.com
Incyte to Highlight Early-Stage Oncology Data at American Associ - GuruFocus
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire
4Q24 earnings stir biopharma stocks, leading to mixed performance - BioWorld MedTech
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - BioSpace
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):